The molecule-targeted therapies for chordomas include [15,16] (1) targeting PDGFR and KIT (imatinib and dasatinib); (2) targeting EGFR and HER2 (erlotinib, lapatinib, gefitinib, and cetuximab); (3) targeting VEGFR (sorafenib, pazopanib, and sunitinib); (4) targeting PI3K/AKT/mTOR pathway (temsirolimus and sirolimus). Here, ERBB2 is linked to chordoma.